Detalhe da pesquisa
1.
Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma.
Br J Haematol
; 180(1): 60-70, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29164606
2.
Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment.
Support Care Cancer
; 25(10): 3217-3224, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28455546
3.
A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma.
Clin Cancer Res
; 26(10): 2346-2353, 2020 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31937615
4.
Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
Lancet Haematol
; 6(1): e38-e47, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30558987
5.
A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma.
Clin Cancer Res
; 25(2): 478-486, 2019 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30279233